Literature DB >> 29268317

The NeoRes trial: questioning the benefit of radiation therapy as part of neoadjuvant therapy for esophageal adenocarcinoma.

Brendon M Stiles1, Nasser K Altorki1.   

Abstract

Entities:  

Year:  2017        PMID： 29268317      PMCID： PMC5723823          DOI： 10.21037/jtd.2017.08.146

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

1.  Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors:  P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

2.  Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.

Authors:  F Klevebro; G Johnsen; E Johnson; A Viste; T Myrnäs; E Szabo; A-B Jacobsen; S Friesland; J A Tsai; S Persson; M Lindblad; L Lundell; M Nilsson
Journal:  Eur J Surg Oncol       Date:  2015-04-08       Impact factor: 4.424

3.  Preoperative Chemoradiation Therapy Versus Chemotherapy in Patients Undergoing Modified En Bloc Esophagectomy for Locally Advanced Esophageal Adenocarcinoma: Is Radiotherapy Beneficial?

Authors:  Jonathan D Spicer; Brendon M Stiles; Monisha Sudarshan; Arlene M Correa; Lorenzo E Ferri; Nasser K Altorki; Wayne L Hofstetter
Journal:  Ann Thorac Surg       Date:  2016-02-23       Impact factor: 4.330

4.  Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus.

Authors:  J F Bosset; M Gignoux; J P Triboulet; E Tiret; G Mantion; D Elias; P Lozach; J C Ollier; J J Pavy; M Mercier; T Sahmoud
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

5.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Authors:  Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

6.  Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.

Authors:  Christophe Mariette; Laetitia Dahan; Françoise Mornex; Emilie Maillard; Pascal-Alexandre Thomas; Bernard Meunier; Valérie Boige; Denis Pezet; William B Robb; Valérie Le Brun-Ly; Jean-François Bosset; Jean-Yves Mabrut; Jean-Pierre Triboulet; Laurent Bedenne; Jean-François Seitz
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

7.  NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.

Authors:  Christoph Schulz; Frank Kullmann; Volker Kunzmann; Martin Fuchs; Michael Geissler; Ursula Vehling-Kaiser; Heribert Stauder; Axel Wein; Salah-Eddin Al-Batran; Thomas Kubin; Claus Schäfer; Sebastian Stintzing; Clemens Giessen; Dominik Paul Modest; Karsten Ridwelski; Volker Heinemann
Journal:  Int J Cancer       Date:  2015-02-25       Impact factor: 7.396

8.  Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.

Authors:  Bryan H Burmeister; Janine M Thomas; Elizabeth A Burmeister; Euan T Walpole; Jennifer A Harvey; Damien B Thomson; Andrew P Barbour; David C Gotley; B Mark Smithers
Journal:  Eur J Cancer       Date:  2011-02       Impact factor: 9.162

9.  A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.

Authors:  F Klevebro; G Alexandersson von Döbeln; N Wang; G Johnsen; A-B Jacobsen; S Friesland; I Hatlevoll; N I Glenjen; P Lind; J A Tsai; L Lundell; M Nilsson
Journal:  Ann Oncol       Date:  2016-01-17       Impact factor: 32.976

10.  ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).

Authors:  Jens Hoeppner; Florian Lordick; Thomas Brunner; Torben Glatz; Peter Bronsert; Nadine Röthling; Claudia Schmoor; Dietmar Lorenz; Christian Ell; Ulrich T Hopt; J Rüdiger Siewert
Journal:  BMC Cancer       Date:  2016-07-19       Impact factor: 4.430
View more
  1 in total

1.  The ideal approach for treatment of cT1N+ and cT2Nany esophageal cancer.: a NCDB analysis.

Authors:  Binhao Huang; Ernest G Chan; Arjun Pennathur; James D Luketich; Jie Zhang
Journal:  BMC Cancer       Date:  2021-12-15       Impact factor: 4.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.